Polycystic Ovary Syndrome

Polycystic ovary syndrome, a common endocrine disorder affecting reproductive-age women, is linked to cardiometabolic disorders that are risk factors for CVD. But the degree of CVD risk in women with polycystic ovary syndrome is still underdetermined.

Women with polycystic ovary syndrome were more likely to have myriad medical conditions, use medications more often and report poorer health than women who did not have the disorder, according to a population-based Finnish study.

ATLANTA — The annual economic burden of mental health disorders associated with polycystic ovary syndrome was estimated to be more than $6 billion, according to a meta-analysis presented here.

ATLANTA — In this video exclusive, Andrea E. Dunaif, MD, lays out the positions for insulin vs. androgens as the cause of polycystic ovary syndrome.

Polycystic ovary syndrome is a common endocrine disorder affecting reproductive-age women, yet the complexity and heterogeneity of PCOS have confounded researchers attempting to understand its long-term consequences.

The hyperandrogenic phenotype of polycystic ovary syndrome is the one most closely related to the things we think are “bad” for cardiovascular disease — obesity, insulin resistance — and those seem to be the driving factors of CVD risk. We also see examples of elevated CV risk in the setting of higher androgen levels in postmenopausal women and transgender men prescribed gender-affirming hormone therapy.

Approximately one in five girls with type 2 diabetes have polycystic ovary syndrome, according to findings of a meta-analysis in JAMA Network Open.

Women with a high genetic risk score for hyperandrogenism have a higher bone mineral density and a lower risk for fracture than those with a lower risk score, according to study results published in Bone.

A new study showed that 3 minutes of moderate-intensity stair walking can lower glucose and insulin concentrations and 10 minutes can improve insulin sensitivity. It was the top story in endocrinology last week.

Combination therapy with a GLP-1 receptor agonist and an SGLT2 inhibitor may provide better weight-loss benefits than a single agent for women with polycystic ovary syndrome and obesity, according to study data.